RFK Jr. and DEA Issue Joint Statement Banning Synthetic 7-OH and Three Opioid Derivatives

Why it matters

The coordinated federal response — with DEA, HHS, and FDA all issuing statements the same day — signals a level of interagency alignment on kratom regulation that has not existed before. HHS Secretary Kennedy's personal statement also brings the kratom policy debate into direct contact with MAHA health agenda.

The big picture

Kratom-derived 7-OH products have proliferated rapidly in convenience stores and online marketplaces, often packaged as candy, gummies, and ice cream cones to appeal to younger consumers. The FDA flagged 7-OH in 2024–2025 as presenting opioid-like addiction risk; the DEA's formal scheduling notice follows the statutory pathway requiring an HHS recommendation before Schedule I placement. Critics of broad kratom bans argue natural leaf products have a legitimate harm-reduction role during the opioid crisis.

Key findings

• DEA classifies 7-OH and three synthetic derivatives (MP, MGM-15, MGM-16) as Schedule I with no accepted medical use and high abuse potential
• The scheduling threshold covers products with more than 0.05% 7-OH by dry weight or more than 1mg per product
• HHS Secretary RFK Jr. said 7-OH, MP, MGM-15, and MGM-16 are dangerous opioids that fuel addiction and put American lives at risk
• Shatterproof, a major addiction advocacy nonprofit, called the action an important and long-overdue step
• Natural botanical kratom leaf without elevated 7-OH is explicitly excluded from the scheduling order
• The ban targets products particularly appealing to children, such as fruit-flavored gummies and candy-like formats

What they say

"I commend the DEA for taking decisive action to address these addictive and harmful substances," said HHS Secretary Robert F. Kennedy Jr. "7-OH, MP, MGM-15, and MGM-16 are dangerous opioids that fuel addiction and put American lives at risk. HHS reviewed the science and recommended this action."

Bottom line

The rare alignment of DEA, HHS, and FDA on 7-OH scheduling — backed by a personal statement from RFK Jr. — substantially accelerates the regulatory timeline for concentrated synthetic kratom products.